# Ectopic FGFR1 Increases Intracellular Pool of Cholesterol in Prostate Cancer Cells

## TL;DR

This study shows that FGFR1 in prostate cancer cells increases cholesterol levels, which may contribute to treatment resistance and suggests targeting FGFR1 as a new therapy.

## Contribution

The study reveals a novel mechanism by which FGFR1 promotes cholesterol accumulation in prostate cancer cells.

## Key findings

- FGFR1 deletion reduces cholesterol pool by lowering LDL uptake and de novo synthesis gene expression.
- FGFR1 activates SREBP2 via ERK, increasing LDLR and cholesterol synthesis enzymes.
- High FGFR1 expression correlates with LDLR levels and poor prostate cancer outcomes.

## Abstract

Prostate cancer (PCa) is the most common male cancer and the second leading cause of cancer death in men. Androgen deprivation therapy (ADT) has been widely used as the first-line treatment for PCa. However, most PCa will progress to castration-resistant PCa (CRPC) that resists ADT 1 to 3 years after the treatment. Steroidogenesis from cholesterol is one of the mechanisms leading to ADT resistance. In PCa cells, low-density lipoprotein (LDL) mediated uptake is the major venue to acquire cholesterol. However, the mechanism of regulating this process is not fully understood. Fibroblast growth factor receptor 1 (FGFR1) is a receptor tyrosine kinase (RTK) that is ectopically expressed in PCa cells and promotes PCa progression by activating downstream signaling pathways. To comprehensively determine the roles of FGFR1 in PCa, we generated FGFR1-null DU145 cells and compared the transcriptomes of FGFR1-null and wild-type cells. We found that ablation of FGFR1 reduced the expression of genes promoting LDL uptake and de novo synthesis of cholesterol, thereby reducing the overall cholesterol pool in PCa cells. Detailed mechanistic studies further revealed that FGFR1 boosted the activation of sterol regulatory element-binding protein 2 (SREBP2) through ERK-dependent phosphorylation and cleavage, which, in turn, increased the expression of low-density lipoprotein receptor (LDLR) and enzymes involved in de novo cholesterol synthesis. Furthermore, in silico analyses demonstrated that high expression of FGFR1 was associated with high LDLR expression and clinicopathological features in PCa. Collectively, our data unveiled a previously unrecognized therapeutic avenue for CRPC by targeting FGFR1-driven cholesterol uptake and de novo synthesis.